scrn -ScreenPro listing will increase DM by .30? Recent information that come out Friday will increase DM substantially in my view. My view
is based upon the following:
Up until Friday I never heard of ScreenPro until it was mentioned on BNN by Robert Mcwhitter. At this broadcast Robert stated DM was the best stock under .50 cents. He then mentioned a private company ScreenPro which may be affiliated with DM in future. ScreenPro currently is a private company and is currently in process of obtaining a listing on CSE and has possible stock code of SCRN. I found it very unusual that Robert mentioned a private company related to DM. He may be participating in upcoming stock placement?
Research of ScreenPro revealed the following:
--ScreenPro Security is a company that looks to eradicate Covid19 through PCR & Rapid testing.
---The directors of ScreenPro are the following:
CEO John Mcmullen
Directors --Paul Haber, Youg Cho Lee, Dr. Sibran Sharif.
All four are involved in the management and directors of DM. I REPEAT ALL FOUR ARE INVOLVED IN MANAGEMENT OF DM.
SO WHAT WE HAVE HERE IN MY OPINION IS THE FOLLOWING:--dm stated that a gross profitof 40% was made on corvid test. On a test of $ 149 we made $ 60.00 and remainder was made by company processing the test. So what we have is other 60% . HERES WHERE SCREENPRO comes into play. DM if takes part ownershipof SCRN new listing it be involved in 100% of test $.
Now I give you the following scenario: ScreenPro has appled for new listing on CSE which may be 30 days away.
ScreenPro lists 100 million shares o/s and lists subscription price of.15cents Initial issue of 40 million shares at.15 which is 6 million dollars. DM TAKES UP 50% OF SHARES at cost of 3 million . Shares will rise with profits to .30 cents in six months?
So what do we have DM makes 40% on receiving order for test and shares other 60% in ScreenPro .
This is my analysis of Robert mentioning DM. He obviously knows something upcoming and probably stands to make substantial amount in investment in DM AND listing oF SCRN.
I welcome views on my analysis.